Register
Login:
Share:
Email Facebook Twitter


HUM CEO updates on the Yanfolila Gold Project now fully funded.


Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 38.125Bid: 37.25Ask: 39.00Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 1.75Spread as %: 4.70%Open: 38.125High: 38.125Low: 38.125Yesterday’s Close: 38.125

Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
38.125

Share Price SpacerBid
37.25

Share Price SpacerAsk
39.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
27,720

Share Price SpacerOpen
38.125

Share Price SpacerHigh
38.125

Share Price SpacerLow
38.125

Share Price SpacerClose
38.125

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 124.64m £47.52m 10,000

52 Week High 48.25 52 Week High Date 2-JUN-2016
52 Week Low 23.00 52 Week Low Date 24-FEB-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
5 17,357 10,363 -8.665 -4.40 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

07-Dec-16
15:48:31
37.85
5,000
Sell* 
37.25
39.00
1,893
Trade Type:
Ordinary

07-Dec-16
14:56:37
38.8075
6,500
Buy* 
37.25
39.00
2,522
Trade Type:
Ordinary

07-Dec-16
12:25:37
38.8233
3,863
Buy* 
37.25
39.00
1,500
Trade Type:
Ordinary




View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
30-Apr-15Notification of Holding
Trade Notifier Information for Immupharma
Stephane Robert George Mery held the position of Non-Executive Director at Immupharma at the time of this trade.
 Stephane Robert George Mery
002259
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
View more Immupharma directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Wed 23:33hunkymonkeyRE: Hunky38.125No Opinion
Thanks boom, #FountainOfKnowledge, as always much appreciated. Is one of the directors of the imm a specialist in Sjogren's syndrome, I'm sure I've read that somewhere along the line. All seems to tie together nicely.

Whether or not the patent raises sp is immaterial to me. It certainly won't raise it enough to tempt me to sell any of my holding to derisk slightly. Here's hoping for a very good December. Good luck all, the next six months should be very interesting indeed
Wed 22:35boomorbustHunky38.125No Opinion
I believe there are a couple of new patent applications currently pending.

1) MODIFIED PEPTIDES AND THEIR USE FOR TREATING AUTOIMMUNE DISEASES

Listed under claim 6:- the family of connective tissue diseases (non specific systemic organ diseases), such as systemic lupus erythematosus (SLE), rheumatoid arthritis, mixed connective tissue disease, Sjogren's syndrome, or chronic juvenile arthritis; and/or organ-specific autoimmune pathologies, such as multiple sclerosis, insulin-dependent… Read More
Wed 19:16hunkymonkeyRE: Lol38.125No Opinion
Astrazenica have 140 clinics recruiting for 450 patients equating to just over 3 patients per person. For their lupus drug.

https://clinicaltrials.gov/ct2/show/record/NCT02446912

First primary data may 2018, also FDA fast track approved.

Our first primary data is June 2017 (on proviso that we recruit for December) with 30 clinics recruiting 200, in fairness I think it would be more like 29 recruiting 180 factoring Mauritius. Equating to just over 6 per… Read More
Wed 18:07leasRE: Lol38.125No Opinion
Lostinfrance, the company have set key targets so I would understand the frustration in recruitment delays. However, having been a long term for some years I do not understand 'your god forbid' statement. The priority here in respect of Lupuzor is a successful trial, not a successful recruitment drive. Investing some patience after investing your hard earned cash will provide you a handsome return.
Wed 16:36LostinfranceRE: Lol38.125No Opinion
Ok thanks, so just a wait for last patient, even if there is a delay we will not be told,
Wed 16:33hunkymonkeyRE: Lol38.125No Opinion
It's one and the same thing. As they cannot be recruited unless they have passed there criteria and screening test, as per the rns about Mauritius, therefore once the final patient is confirmed, there would be no reason to delay the dosing of said patient. I doubt that there would be an Rns to confirm 200 and then another to confirm the last is being dosed. Interestingly, the first patients dosed are close to finishing the trial (February 2017)
Clearly that indicates no serious adverse affects… Read More

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.